0114 232 9292 connect@medilink.co.uk

Huddersfield company travels to Texas to promote UK healthcare innovation

A Huddersfield scalp cooling manufacturer is one of 9 UK companies representing the country’s health and life science industry in Texas next week.

Paxman, who manufacture and supply an innovative medical device for the prevention of chemotherapy-induced alopecia (CIA), will form part of a delegation consisting of innovative medical technology companies. It is the first time a health delegation of this kind has visited the state and is the first trip of an 18-month programme.

Organised by the British Foreign and Commonwealth Office (FOC), its trade investment body (UKTI) and the UK’s medical technology industry body, the Association of British Healthcare Industries (ABHI), the select delegation of medical technology pioneers will travel to Austin, San Antonio and Houston.

After eight months of planning with medical centres, university hospitals and the United States Armed Forces, the British visitors will meet with Texan hospitals and life sciences organisations. The objective of the visit is to foster new relationships to develop and adopt cutting-edge medical technologies in the state.

For Texan-based companies, it provides an important opportunity to learn about and engage with the UK’s health system and understand how the market works.

The delegation’s members come from companies whose products and services are truly life changing. The Paxman scalp cooler enables patients to retain their hair by having non-invasive scalp cooling treatment, which is administered during chemotherapy infusion.

With over 2,000 machines in use in clinics, hospitals, and the home healthcare setting worldwide, tens of thousands of cancer patients have been successfully treated. Approximately 60-70% of patients using this technology retain most, if not all of their hair.

As a global business with family roots, Paxman aim to make a difference to people’s lives by raising awareness and establishing scalp cooling as common practice; constantly striving to gain further knowledge and understanding of chemotherapy-induced alopecia.

The company is currently embarking on a multi-centre trial across the US in a bid to gain FDA approval. The trial is taking place in Dallas, Houston, New Jersey and Ohio.

Speaking ahead of the visit, Richard Paxman, CEO of Paxman, said: “We are currently nearing the completion of our US clinical study so this trade mission offers the perfect platform for us.”

“We believe it will help us strengthen our commercialisation strategy and build new relationships with hospital networks and potential investors. It will also help us create an awareness and future demand for our scalp cooler in the US and help us understand the most suitable locations in Texas to establish a presence.”

It is recognised that the UK has a world-leading reputation in life sciences. Its £18bn ($26.3) medical technology sector employs over 88,000 people and has changed millions of lives across the globe.

Peter Ellingworth, ABHI’s Chief Executive Officer, says: “We are very excited to be strengthening relationships for the medical technology sector between the UK and the state of Texas.

“I know there is a huge amount we can learn from one another. We are honoured to be hosted by the state of Texas, as it works to become a world leader in health and life sciences.”

paxman

Comments are closed.